明德生物(002932.SZ):擬出資500萬元設立湖南明德醫療科技有限公司
格隆匯11月20日丨明德生物(002932.SZ)宣佈,公司擬投資設立全資子公司“湖南明德醫療科技有限公司”(暫定名,最終以工商部門核准登記為準)。擬成立的子公司註冊資本為500萬元,公司將以自有資金出資,佔其全部股權的100%。
湖南明德醫療科技有限公司法定代表人為趙英穩,經營範圍包括一類、二類和三類醫療器械(憑有效的許可證經營)生產、研製、銷售及租賃;普通實驗室試劑(不含危險化學品、易製毒化學品)銷售等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.